
1. nat commun. 2018 aug 17;9(1):3314. doi: 10.1038/s41467-018-05652-0.

emerging southeast asian pfcrt mutations confer plasmodium falciparum resistance 
to first-line antimalarial piperaquine.

ross ls(1), dhingra sk(1), mok s(1), yeo t(1), wicht kj(1), kümpornsin k(1)(2),
takala-harrison s(3), witkowski b(4), fairhurst rm(5)(6), ariey f(7), menard
d(4)(8), fidock da(9)(10).

author information: 
(1)department microbiology immunology, columbia university irving medical 
center, 1502 hammer health sciences center, 701 w. 168th st., new york, ny,
10032, usa.
(2)parasites microbes, wellcome sanger institute, wellcome genome campus,
hinxton, cambridge, cb10 1sa, uk.
(3)center vaccine development global health, university maryland
school medicine, 685 w. baltimore street, baltimore, md, 21201, usa.
(4)malaria molecular epidemiology unit, pasteur institute cambodia, po box
983, phnom penh, cambodia.
(5)laboratory malaria vector research, niaid, nih, 12735 twinbrook
parkway, bethesda, md, 20852, usa.
(6)parasitology international programs branch, dhhs, niaid, nih, rockville,
md, 20852, usa.
(7)cochin institute inserm u1016, university paris descartes, laboratory of
parasitology-mycology, cochin hospital, 22 rue méchain, 75014, paris, france.
(8)malaria genetic resistance group, biology host-parasite interactions
unit, pasteur institute, 25-28 rue du dr. roux, 75724, paris, france.
(9)department microbiology immunology, columbia university irving medical 
center, 1502 hammer health sciences center, 701 w. 168th st., new york, ny,
10032, usa. df2260@cumc.columbia.edu.
(10)division infectious diseases, department medicine, columbia university 
irving medical center, new york, ny, 10032, usa. df2260@cumc.columbia.edu.

the widely used antimalarial combination therapy dihydroartemisinin + piperaquine
(dha + ppq) failed cambodia. here, perform genomic analysis that
reveals rapid increase prevalence novel mutations plasmodium
falciparum chloroquine resistance transporter pfcrt following dha + ppq
implementation. mutations occur parasites harboring k13 c580y
artemisinin resistance marker. introducing pfcrt mutations sensitive dd2 
parasites removing resistant cambodian isolates, show the
h97y, f145i, m343l, g353v mutations confer resistance ppq, albeit with
fitness costs m343l. mutations sensitize dd2 parasites to
chloroquine, amodiaquine, quinine. dd2 parasites, multicopy plasmepsin 2, 
a candidate molecular marker, necessary ppq resistance. distended
digestive vacuoles observed pfcrt-edited dd2 parasites in
cambodian isolates. findings provide compelling evidence emerging
mutations pfcrt serve molecular marker mediator ppq
resistance.

doi: 10.1038/s41467-018-05652-0 
pmcid: pmc6095916
pmid: 30115924  [indexed medline]

